Skip to main content
Clinical Trials/NCT00359047
NCT00359047
Active, not recruiting
Not Applicable

Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme

CHU de Quebec-Universite Laval1 site in 1 country2,830 target enrollmentJune 2003
ConditionsOsteoporosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoporosis
Sponsor
CHU de Quebec-Universite Laval
Enrollment
2830
Locations
1
Primary Endpoint
The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

The aim of the ROCQ programme is to improve the use of evidence based osteoporosis diagnostic and treatment strategies for women 50 years and over who have suffered a fragility fracture. This objective will be achieved by concentrating on a realistic evaluation of the present diagnosis and treatment rate of osteoporosis following a fragility fracture and comparing it to an optimal situation (care gap) and proposing interventions that promote new approaches to treating osteoporosis by health professionals as well as providing targeted interventions for the patient. The efficacy of these interventions will be evaluated using a randomized control design.

Detailed Description

ROCQ is a patient health-management programme and prospective cohort study. Within the ROCQ programme, educational interventions to improve osteoporosis management will be evaluated using a randomized-control design. The programme is composed of a promotional campaign, three main phases and a 20-year follow-up. At phase 1, 0 to 16 weeks after the fracture, participants with fragility and traumatic fractures will be recruited and will be asked information regarding their fracture. At phase 2, 6 to 8 months after the fracture, all participants will complete questionnaires to evaluate demographic and clinical features, risk factors for osteoporosis, co-morbidities, status of diagnosis and treatment, and the EQ-5D. The current medical management of osteoporosis (or the care gap in diagnosis and treatment) will be measured using this questionnaire at phase 2. Once the phase 2 questionnaire has been completed, Only participants with fragility fractures will be randomized to one of the three following educational intervention groups: 1) the Educational Video Group, 2) the Documentation Group, or 3) the Control Group. At phase 3, 12 to 14 months after randomization, the effectiveness of the interventions will be assessed by re-administering the questionnaires to participants who experienced a fragility fracture at baseline. The questionnaires evaluate the status of diagnosis and treatment of osteoporosis, modifiable risk factors and the health-related quality of life (EQ-5D). The impact of the interventions on the participants will be assessed by comparing diagnosis and treatments rates in each intervention arm. If the long-term viability of the programme is secured, participants with fragility and traumatic fractures will be followed for a maximum period of 20 years using specific encoded personal data contained in the RAMQ and Quebec's drug plan databases.

Registry
clinicaltrials.gov
Start Date
June 2003
End Date
December 2025
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
CHU de Quebec-Universite Laval
Responsible Party
Principal Investigator
Principal Investigator

Jacques Brown

Clinical researcher

CHU de Quebec-Universite Laval

Eligibility Criteria

Inclusion Criteria

  • Female, aged 50 years and over.
  • Not residing in a long-term care hospital before the fracture.
  • Able to understand the programme information and consent form.
  • Must voluntarily accept to participate in this programme and sign the consent form.
  • Participants must have a fragility or traumatic fracture of one of the following sites: wrist, forearm, humerus, scapula, clavicle, sternum, thoracic or lumbar vertebrae, pelvis, sacrum, hip, femur, proximal and distal tibia, fibula (including ankle), and foot.
  • Participants must be able to answer the questionnaires via phone interviews

Exclusion Criteria

  • Unable to understand the purpose of the programme.
  • Participants with a traumatic fracture of one of the following sites: cervical, skull and face, hand and finger, toe, metatarsus, and patella.
  • Pathological fracture.
  • Women currently participating in a clinical trial requiring them to take a medication for osteoporosis.

Outcomes

Primary Outcomes

The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions

Time Frame: June 2007

The average 5-year, 10-year, 15-year, and 20-year probabilities of a fragility fracture by age, site of previous fragility fracture, and type of ROCQ intervention.

Time Frame: July 2009

The present diagnostic and treatment rates of osteoporosis 6 months after a fragility fracture

Time Frame: June 2007

Secondary Outcomes

  • One-year mortality rate following a fragility fracture.(May 2009)
  • Changes of modifiable risk factors for osteoporosis 12 months after the intervention(September 2009)
  • Proportion of fragility versus traumatic fractures.(June 2007)
  • Health care resource utilization associated with specific types of fragility fracture and recurrent fractures.(September 2010)
  • Satisfaction with the process of care before and after implementing ROCQ's interventions.(June 2010)
  • Incidence of recurrent fracture and health care resources utilization between women who previously had a fragility fracture and those who had a traumatic fracture.(November 2010)
  • Assess health utility index (EQ-5D) after a fragility fracture.(September 2010)
  • Persistence to pharmacological treatment 12 months after the intervention(October 2009)

Study Sites (1)

Loading locations...

Similar Trials